Cancer Center Community Advisory Board Archives - Sanford Burnham Prebys
Institute News

Melanoma’s mysteries revealed at Sanford Burnham Prebys

AuthorGreg Calhoun
Date

March 26, 2024

Cancer Center open house welcomes San Diego community to learn the latest about melanoma research

The Institute’s NCI-designated Cancer Center hosted the open house on Wednesday, March 20. It provided an opportunity for community members to meet scientists who seek to better understand melanoma and use this knowledge to improve treatment and prevention.

The event was sponsored by the center’s Community Advisory Board, an eight-member committee that focuses on advocacy, education and community engagement, as well as providing Cancer Center leaders and members with the perspectives of patients, survivors and their loved ones.

Open house participants could select from a variety of activities. Two labs provided brief poster presentations.

Ze’ev Ronai, PhD, director of the Sanford Burnham Prebys Cancer Center and the Jeanne and Gary Herberger Leadership Chair in Cancer Research, and his team discussed several areas of research, including the dissection of microbiota commensals which support the immune system’s fight against melanoma, the studies undertaken to understand melanoma addiction to the metabolic enzyme GCDH, and the development of new drugs to target the molecular machine that translates genetic instructions into proteins, which are known to be hyperactive in cancer cells.

Linda Bradley, PhD, professor in the Cancer Metabolism and Microenvironment Program at Sanford Burnham Prebys, and her group detailed their work on improving the immune system response to viral infections and cancer, including a new potential immune checkpoint therapy and efforts to rejuvenate overstressed immune cells to enhance the effectiveness of immunotherapy.

Attendees also could take tours of two different research facilities. Many participants enjoyed an insider’s view into the field of cryo-electron microscopy (cryo-EM), a technology that garnered three key innovators the 2017 Nobel Prize in Chemistry. The Cryo-EM core facility enables scientists to create 3D images of the cell and all its constituent parts that are accurate to the tiniest detail as it is able to capture individual atoms. Images taken using cryo-EM can be organized sequentially to develop films that show in real time how the cell’s many actors interact, helping scientists map interactions between drugs identified at Sanford Burnham Prebys and their target proteins, thereby advancing novel modalities for the treatment of melanoma and other cancers.

The second tour brought community members to the Conrad Prebys Center for Chemical Genomics. The Prebys Center is the Institute’s comprehensive center for drug discovery and chemical biology. Visitors were able to see the center’s state-of-the-art robots that enable researchers to quickly test the potential effectiveness of hundreds of thousands of compounds to find new prospective treatments. Many scientists at Sanford Burnham Prebys partner with the Prebys Center to conduct drug discovery searches based on new research findings, including those studying melanoma and other cancers.

Open House guests conversing in Chairmen's HallMany of the visitors had the opportunity to visit a melanoma research laboratory to learn about research projects in the Ronai lab and view melanoma cells as seen under the microscope.

Following the tours, Ronai shared an overview of the Cancer Center and highlighted recent accomplishments. Attendees interacted with Gregory Daniels, MD, PhD, a medical oncologist and melanoma expert from University of California San Diego and Steven Silverstein, a melanoma survivor, former president of the Melanoma Research Foundation and a melanoma research advocate. The open house concluded with an opportunity for guests to speak with cancer scientists and featured speakers during the evening reception.

“We were honored to provide our valued guests with the opportunity to learn about the research conducted at our Cancer Center, including ongoing melanoma research,” says Ronai. “Our open houses, which focus on different unmet needs in cancer, allow us to welcome and engage with the San Diego community, to share our findings and be inspired by patients and their loved ones.”

Institute News

Behind the scenes at Sanford Burnham Prebys’ Cancer Center

AuthorMiles Martin
Date

March 28, 2023

Cancer Center open house connects San Diego community with scientists working toward cancer cures

The Institute’s NCI-designated Cancer Center hosted an open house to showcase the latest research advances in cancers of the digestive system. The event was sponsored by the center’s Community Advisory Board (CAB), which provides a link to community networks of people—including patients, survivors and their loved ones.

“These events are especially helpful for people affected by cancer because our researchers can explain the science behind the disease and the approaches we use to find new treatments,” says Associate Professor Cosimo Commisso, PhD, who co-hosted the event with Adjunct Associate Professor Pamela Itkin-Ansari, PhD “As researchers, it’s critical that we have community participation to influence our research—so we benefit as well.” 

The open house, which was free to the public, fulfills a key part of the CAB’s mission—to create awareness of the cancer research being done at the Institute and to promote dialogue between its scientists and the community. Guests had the chance to mingle with cancer researchers, and there was also a panelist table, where they could ask questions directly to a panel including two cancer survivors and a clinician.

The theme of the open house was cancers of the digestive system, which includes pancreatic cancer, liver cancer, stomach cancer and colorectal cancer. Although these cancers are very diverse, one thing many cancers of the digestive system have in common is that they take a long time to diagnose and are difficult to treat. 

“These are devastating cancers,” says Commisso. “We’ve doubled the survival rates for pancreatic cancer since I started working in this field over a decade ago, but it’s still only around 10%. And that’s just not good enough.”

Attendees also got behind-the-scenes tours of labs, including Commisso’s, where researchers are working to halt pancreatic cancer by blocking nutrients—in essence, starving tumor cells of the fuel they need to grow and proliferate. 

“We have a lot of researchers taking different approaches to cancer here at the Institute, and it’s important for people affected by cancer to know that while we’re still a long way off from ending cancer forever, we’re still making progress,” adds Commisso.

Institute News

Advocates for our Cancer Center ensure patient perspective is understood in the lab

AuthorJosh Baxt
Date

August 20, 2021

Helen Eckmann and Ruth Claire Black share a common history with breast cancer and a drive to serve their community.

Ruth Claire Black and Helen Eckmann are sisters from different parents. They both have doctorates, work as professors and volunteer for Sanford Burnham Prebys’ Cancer Advisory Board (CAB).

Black and Eckman are incurable optimists and are both thriving after breast cancer. They want other cancer survivors to feel the same way.

“One of the messages we like to deliver is that you can live an amazing, vibrant, positive, productive, fully engaged-in-your-community life,” says Black, “even after fully metastasized, stage 4 breast cancer.”
 

Parallel journeys

Black knew all along that she was going to face breast cancer. Both her grandmother and mother died from the disease when they were in their 50s. That shoe dropped for her, as expected, around her 50th birthday.

“I got my diagnosis on a Thursday before a long Memorial Day weekend,” says Black. “I kept calling in, getting the switchboard and becoming increasingly anxious. But I was lucky. I had people I could call to talk me off the ledge.”

One of her impromptu counselors was Helen Eckmann.

Eckmann was initially diagnosed when she was 42, the first of three bouts with the disease. Following an inconclusive mammogram, Eckmann was instructed to come back in six months, but a sudden epiphany brought her back sooner.

“I was putting on a pair of shoes, and I think God spoke to me and said, ‘Go now!’” says Eckmann. “I told the doctor I wanted a needle biopsy to figure out whether it was actually cancer. They told me not to worry about it, to wait the full six months, but I insisted. At that point, the cancer had already moved into my lymph system.”

That was just the beginning of her long journey, including multiple rounds of chemotherapy and surgery. “About six years ago, I was going up the stairs, and my right femur broke,” says Eckmann. “The cancer had gone to my bones.”
 

From Experience to Advocacy

Eckmann and Black were knocked down repeatedly by breast cancer, but they kept getting back up. During these treatment odysseys, each developed a profound ability to see the disconnects in the system: the oncologists who wouldn’t take their intuition seriously (but soon learned better); the insurance companies that seemed to make random coverage decisions; the difficulty finding timely, accurate information.

“I’m a lawyer, a professor and I’ve worked a lot as a consultant,” says Black. “But even with that background, I didn’t know what I needed to know to successfully move through treatment. I think that’s a common theme.”

Both wanted to find productive ways to give back. Eckmann was one of the earliest members of the Sanford Burnham Prebys’ NCI-designated Cancer Center’s Community Advisory Board, which includes cancer survivors and family members who’ve supported a loved one through treatment. She recalls her conversation, many years ago, with President Kristiina Vuori, MD, PhD, who was the Cancer Center director at the time.

“I told her I wanted to help, and she leaned across the desk and practically hugged me,” said Eckmann. “She said she was going to put me to work, and she did.”

Helen Eckmann and Ruth Claire Black

Black joined a few years later. Together with seven fellow CAB members, they organize public events to educate the community about cancer research, teach scientists how to communicate their work to lay audiences and help principal investigators with their grant applications.

“Part of the Department of Defense’s (DOD’s) Breast Cancer Research Program grant assessment process is measuring community support for the research,” says Black. “We act as advocates, providing support letters and making sure the patient experience is understood in the lab.”

This is no small piece. Dedicated lab scientists spend much of their time conducting research. And while this often gives them great insights into cancer biology, and possible interventions, it can also create blind spots.

“One time I was at a lab meeting, and they were talking about an experiment that would require patients to give blood samples every month or so,” says Black. “But that’s a high burden to place on people who may not have an extra two hours in their schedule. The lab’s focus was on how to collect these biomarkers sequentially over time, but they hadn’t really thought about the patients. This was a new perspective for them, and they were really open to it.”

Both Eckmann and Black have steadily elevated their game and are now part of the DOD’s Consumer Review Program, in which they rate grant proposals for their potential impact on patients. Eckmann has also joined NCI Cancer Center accreditation visits, and Black is on the Food & Drug Administration’s National Mammography Quality Assurance Advisory Committee.

All these efforts are driven by their concerns for fellow cancer patients and survivors. They clearly remember those early days, soon after diagnosis, when they didn’t understand their roles as patients, insisted on working and keeping their normal hectic schedules and tried to pretend that nothing was wrong.

Over time, they learned that cancer treatment is a marathon, and that it’s easy for people to waste tremendous energy on issues beyond their control until they have nothing left in the tank. However, they also want their peers to know that, yes, a cancer diagnosis is horrific, but it will help people find resilience they never knew they had.

“The journey will make you stronger for sure,” says Black, “whether you want to be stronger or not.”

Institute News

On the path to personalized breast cancer treatments

AuthorMonica May
Date

October 24, 2019

Ruth Claire Black wasn’t entirely surprised when she was diagnosed with breast cancer six and a half years ago. Her mother had died at age 52 of breast cancer, only two years after she was first diagnosed, Black explained at our recent Fleet Science Center event. New treatments have allowed Black’s story to differ from her mother’s—but as breast cancer experts from Sanford Burnham Prebys and UC San Diego Health explained, there is still a long way to go. 

“There is a great misconception that breast cancer is extremely easy to treat and is always cured. But the truth is that one in three women with early-stage breast cancer will relapse and eventually die from the disease,” said speaker Rebecca Shatsky, MD, a breast cancer oncologist at UC San Diego Health. “We are learning there aren’t one or two kinds of breast cancer—there are up to 30 different subtypes. To cure breast cancer, we need to look at treatments through a personalized lens.” 

Breast cancer is the second most common cancer in American women. One in eight women will be diagnosed with breast cancer in her lifetime, and more than 40,000 women die each year from the cancer. Targeted treatments—such as those that block the HER2 receptor—and hormone-based therapies have extended survival. However, 30% of people with estrogen-positive breast cancer, the most common form, eventually stop responding to standard-of-care treatments, for reasons that are largely unknown.

Speaker Svasti Haricharan, PhD, assistant professor at Sanford Burnham Prebys, is working to change these realities. Her work centers on a breast cancer subtype caused by defects in DNA repair machinery—a genomic “spell check” that normally corrects DNA copy errors during cell division. Nearly 20% of people who do not respond to breast cancer treatment have mutations in this machinery. Working with Shatsky, Haricharan’s team identifies breast cancer samples that have DNA damage repair defects. Then she tests these samples against thousands of FDA-approved treatments—with the goal of finding an effective treatment. 

For people like Black, these advances can’t come soon enough. 

“We have so much information about breast cancer. We have great diagnostics. Because of these tests, I know I’m a carrier of the BRCA2 mutation. I also know that it’s only a matter of time until my cancer returns,” said Black, who is a member of Sanford Burnham Prebys’ Community Advisory Board. “But doctors don’t know what to do with all of this information. That’s why I’m so supportive of the work taking place at Sanford Burnham Prebys. They are taking this information and doing something with it.” 

This event was the third of our five-part “Cornering Cancer” series. Register today to join us for discussions on pancreatic cancer in November and pediatric brain cancer in December. 
 

Institute News

Stepping into a scientist’s shoes at the Cancer Center Open House

AuthorMonica May
Date

June 20, 2019

Cancer research has led to new insights and novel medicines that have transformed the lives of parents, grandparents and children around the world. Yet cancer remains the number-one cause of death in San Diego (nationally, it is the second-leading cause of death). The quest for new and better treatments—and a world free of the disease—remains urgent. 

On June 13, 2019, the San Diego community—including many cancer survivors and their loved ones—had a unique opportunity to step into the shoes of a cancer researcher and see how cancer drugs are discovered at the open house of our NCI-designated Cancer Center. The facility is one of only seven National Cancer Institute (NCI)–designated basic research cancer centers in the nation. 

Following an introduction by Garth Powis, D. Phil., professor and director of the NCI-designated Cancer Center, guests embarked on guided lab tours. Attendees discovered how we’re working to find better ways to combat cancer, viewed highly specialized equipment—such as machines that model the low-oxygen environment surrounding a tumor—and donned lab coats to catch a glimpse of our ultra-high-throughput drug screening robot in action at our Prebys Center for Drug Discovery. The state-of-the-art technology at the Prebys Center can screen hundreds of thousands of potential drug candidates in one run, accelerating the time it takes to find new, promising compounds that may become tomorrow’s cancer treatments.

Guests also learned how San Diego, with a multitude of world-class research institutes, universities and biotech companies, is shaping the future of cancer diagnosis and treatment. And our Community Advisory Board, comprised of cancer research advocates and cancer survivors, were on hand to share the importance of factoring in patients’ perspectives as breakthrough science moves from “bed to bedside.”

See the science in action in these event photos.

Missed the event? We hope you can join us at our next open house in November. The event is free and open to the public. Check for more details at sbpdiscovery.org/calendar.

Many thanks to our Community Advisory Board (CAB), the host of the open house. Comprised of nine cancer research advocates, including many cancer survivors, this committee strives to create a dialogue between our scientists and the community. We are grateful for CAB’s efforts surrounding the event, which included helping our scientists prepare lay-friendly presentations and posters that were critical to the event’s success.

Interested in keeping up with our latest discoveries, upcoming events and more? Subscribe to our monthly newsletter, Discoveries.

Institute News

Cancer Center Open House Showcases SBP Scientists

AuthorHelen Hwang
Date

November 14, 2017

SBP’s Cancer Center Open House on November 9, 2017 enlightened visitors from the community on the topic of “The Science Behind Personalized Cancer Medicine,” as four diverse scientific labs showcased posters and demonstrated how we are  translating biomedical research into innovative treatments for patients.

 

Garth Powis, D.Phl.., head of the National Cancer Institute-designated Cancer Center at SBP, said the Open House “provides a service to those who have been touched by cancer in some way. By sharing our latest research, we want to be able to show that there is hope, that we are making advances, and at this Open House in particular, share how new technologies are changing the way we conduct our research, and eventually bring our discoveries to cancer patients.”

 

One of the labs featured was SBP President, Kristiina Vuori, Ph.D., a respected scientist with wide-ranging research that includes brain cancer and acute myeloid leukemia (AML). Ben Finlay, PhD, emphasized how important “collaboration was at SBP” and explained how researchers work closely with Scripps Blood and Marrow Transplant Program to collect patient tumor samples to find a cure for AML.

 

Robert Wechsler-Reya, PhD, who discussed personalized cancer care for children with brain tumors. As a world-renowned expert on medulloblastoma, Dr. Wechsler-Reya also works closely with doctors at Rady Children’s Hospital to discuss individual pediatric tumor cases, in addition to his role as SBP researcher.

 

Michael Jackson, PhD, senior vice president, led the tour of the Prebys Center for Drug Discovery where he demonstrated the high-speed drug screening robot arm in action, showing how state-of-the-art technology is a vital tool in testing new drugs to find cancer cures.

 

“Decoding tumor response at the single-cell level” was the topic featured in the laboratory of Peter Adams, Ph.D. Simply put, if you treat a tumor and kill 99 percent of the cancer cells, but 1 cell left contains a mutation that can cause the tumor to grow again, the cancer treatment isn’t effective for the patient. By better understanding each cell, science can translate into robust treatments. 

 

The public event, which attracted more than 140 people, included a wide array of visitors from a busload of high school biology students from Monte Vista High School to Board Trustees. For some people, it was the first time they visited our Institute to learn about our pioneering research while others took the opportunity to revisit old friends and a scientific organization they support with great passion.

 

Your support is so important to continuing our research. Click to donate now.

 

Check out the Facebook album of the Cancer Center Open House. 

 

The next Cancer Center Open Houses will be held on Thursday, June 14, 2018 and Thursday, November 8, 2018. Please check back for more details and registrations.